Hostname: page-component-89b8bd64d-nlwjb Total loading time: 0 Render date: 2026-05-10T21:55:16.535Z Has data issue: false hasContentIssue false

Stimulant medication for the treatment of attention-deficit hyperactivity disorder: evidence-b(i)ased practice?

Published online by Cambridge University Press:  02 January 2018

Lionel Bailly*
Affiliation:
NEMHP NHS Trust, Royal Free and UCL Medical School, Wolfson Building, 48 Riding House Street, London W1N 8AA, e-mail: rejulba@ucl.ac.uk
Rights & Permissions [Opens in a new window]

Extract

Attention-deficit hyperactivity disorder (ADHD) and its pharmacological treatment remain the objects of intense controversy. The conflict reaches far beyond the area of scientific debate. An article on ‘behavioural syndromes', published in The Times on 28 July 2003, was headlined: ‘Hyperactive? Just go to a park and climb a tree’. An internet search will produce equal numbers of sites warning either that the prescription of stimulant medication is a denial of children's human rights, or that not prescribing stimulant to an ADHD child denies their right to treatment.

Information

Type
Opinion & debate
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2005. The Royal College of Psychiatrists
Submit a response

eLetters

No eLetters have been published for this article.